niacinamide has been researched along with Erythema Multiforme in 9 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Erythema Multiforme: A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic bull's-eye lesions usually occurring on the dorsal aspect of the hands and forearms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Erythema multiforme (EM) is a known side effect of sorafenib therapy in cancer patients; at onset, the causative medication should be permanently discontinued." | 7.80 | [Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma]. ( Andoh, A; Bamba, S; Fujiyama, Y; Inatomi, O; Nishida, A; Nishimura, T; Sasaki, M; Shioya, M, 2014) |
| "Sorafenib-induced erythema multiforme may not be rare in Japanese patients." | 7.78 | Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. ( Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S; Satoh, T; Tabata, K; Tanabe, K, 2012) |
| "The authors present a case of erythema multiforme-like drug reaction to the multikinase inhibitor sorafenib." | 7.77 | Erythema multiforme-like drug reaction to sorafenib. ( Farley-Loftus, R; Lewin, J; Pomeranz, MK, 2011) |
| "Sorafenib is a new therapeutic agent being used in metastatic renal cell carcinoma, hepatocellular carcinoma, and malignant melanoma." | 5.35 | Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma. ( Bilaç, C; Ermertcan, AT; Kayhan, TC; Müezzinoğlu, T; Oztürkcan, S; Temeltaş, G; Temiz, P, 2009) |
| "Erythema multiforme (EM) is a known side effect of sorafenib therapy in cancer patients; at onset, the causative medication should be permanently discontinued." | 3.80 | [Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma]. ( Andoh, A; Bamba, S; Fujiyama, Y; Inatomi, O; Nishida, A; Nishimura, T; Sasaki, M; Shioya, M, 2014) |
| "Sorafenib-induced erythema multiforme may not be rare in Japanese patients." | 3.78 | Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. ( Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S; Satoh, T; Tabata, K; Tanabe, K, 2012) |
| "The authors present a case of erythema multiforme-like drug reaction to the multikinase inhibitor sorafenib." | 3.77 | Erythema multiforme-like drug reaction to sorafenib. ( Farley-Loftus, R; Lewin, J; Pomeranz, MK, 2011) |
| "Sorafenib is a new therapeutic agent being used in metastatic renal cell carcinoma, hepatocellular carcinoma, and malignant melanoma." | 1.35 | Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma. ( Bilaç, C; Ermertcan, AT; Kayhan, TC; Müezzinoğlu, T; Oztürkcan, S; Temeltaş, G; Temiz, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shioya, M | 1 |
| Nishimura, T | 1 |
| Nishida, A | 1 |
| Inatomi, O | 1 |
| Bamba, S | 1 |
| Sasaki, M | 1 |
| Andoh, A | 1 |
| Fujiyama, Y | 1 |
| Pichard, DC | 1 |
| Cardones, AR | 1 |
| Chu, EY | 1 |
| Dahut, WL | 1 |
| Kong, HH | 1 |
| Feltes, RA | 1 |
| Feito Rodríguez, M | 1 |
| González-Beato, MJ | 1 |
| Bilaç, C | 1 |
| Müezzinoğlu, T | 1 |
| Ermertcan, AT | 1 |
| Kayhan, TC | 1 |
| Temeltaş, G | 1 |
| Oztürkcan, S | 1 |
| Temiz, P | 1 |
| Kodaira, M | 1 |
| Takahashi, S | 1 |
| Takeuchi, K | 1 |
| Yuasa, T | 1 |
| Saotome, T | 1 |
| Yonese, J | 1 |
| Fukui, I | 1 |
| Hatake, K | 1 |
| Lewin, J | 1 |
| Farley-Loftus, R | 1 |
| Pomeranz, MK | 1 |
| Ikeda, M | 1 |
| Fujita, T | 1 |
| Mii, S | 1 |
| Tanabe, K | 1 |
| Tabata, K | 1 |
| Matsumoto, K | 1 |
| Satoh, T | 1 |
| Iwamura, M | 1 |
| MacGregor, JL | 1 |
| Silvers, DN | 1 |
| Grossman, ME | 1 |
| Sherman, WH | 1 |
| Walther, H | 1 |
9 other studies available for niacinamide and Erythema Multiforme
| Article | Year |
|---|---|
[Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erythema Multiforme; Female; Humans; Liver N | 2014 |
Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Erythema Multiforme; Humans; Male; Niacinamide; Phenylu | 2016 |
Erythema multiforme induced by sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema Mul | 2009 |
Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; E | 2009 |
Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Ery | 2010 |
Erythema multiforme-like drug reaction to sorafenib.
Topics: Adult; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions; Erythema Multiforme; Female; Hand | 2011 |
Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant | 2012 |
Sorafenib-induced erythema multiforme.
Topics: Administration, Oral; Benzenesulfonates; Erythema Multiforme; Female; Humans; Lung Neoplasms; Melano | 2007 |
[Erythema exsudativum multiforme as a symptom for a general disease. Simultaneous case report: Wegener's granulomatosis and erythema exsudativum multiforme].
Topics: Chronic Disease; Erythema Multiforme; Female; Granuloma; Granulomatosis with Polyangiitis; Humans; M | 1971 |